The retrospective trial is observational, intended to stand alone, complement and integrate data collected in ongoing clinical studies to aid in establishing payor coverage in the United States (U.S.) for Cellution Biologics allograft products with real-world evidence to support the clinical adoption in patients to manage chronic or surgical wounds.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* 18 years of age or older.
* Wound treated with Cellution Biologics AmchoPlast, a dehydrated human placental tissue (dHPT).
* Wound present for greater than or equal to 30 days prior to treatment with dHPT.
* Wound is not infected.
* Wound surface area is greater than 1cm2 at initial assessment.
* Clinical documentation of wound treatment.
Exclusion Criteria:
* AmchoPlast dHPT product was not applied to wound.
* HbA1C \>12%.
* Presence of active osteomyelitis.
* Concurrent treatment for malignant disease.
* Use of other advanced biologics during treatment period.
Primary outcome measure(s)
Time to Closure for Target Ulcer — Up to 8 months. To evaluate the time to wound closure for patients treated with dHPT.
Trial sites (1)
Facility
City
Region
Status
001
Chicago
Illinois
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.